Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Articles|November 15, 2013
- NSCLC (Issue 1)
- Volume 1
- Issue 1
The Treatment of Lung Cancer Subgroups
Author(s)Chandra P. Belani, MD
Chandra P. Belani, MD, from the Penn State Hershey Cancer Institute, discusses the treatment of subgroups of patients with lung cancer.
Advertisement
Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the treatment of subgroups of patients with lung cancer.
Read more abouttreating squamous and nonsquamous diseas
Articles in this issue
almost 13 years ago
Molecular Targeted Agents for Stage III NSCLCalmost 13 years ago
Molecular Targets in Non-Small Cell Lung Canceralmost 13 years ago
Multidisciplinary Perspectives: Molecular Testing in NSCLCalmost 13 years ago
World Conference on Lung Cancer 2013 Highlightsalmost 13 years ago
Guidelines for Molecular Testing in Lung Canceralmost 13 years ago
Treating Squamous vs Nonsquamous DiseaseAdvertisement
Related to this article
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
3
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5